CBD-Intel will provide comprehensive market and legal analysis as well as a daily news service, and like ECigIntelligence, it will be based on a paid subscription model. The online publication and research resource was launched this week and will be the first to focus on the fast-growing CBD industry in Europe and worldwide.
CBD, or cannabidiol, is the legal extract of the cannabis plant which is used for the treatment of a number of health conditions. Despite derived from Cannabis, it does not induce the physical dependence or altered states of consciousness associated with its consumption.
The study found evidence that the oil has positive results in the treatment of Â Alzheimerâ€™s disease, cancer, psychosis, Parkinsonâ€™s disease, and other serious conditions.
In fact, a recent the WHO report finally recognized the number of medical applications that CBD can have, saying that it has â€śbeen demonstrated as an effective treatment for epilepsyâ€ť in adults, children, and even animals. Additionally this research had found â€śpreliminary evidenceâ€ť that the substance has positive results in the treatment of Â Alzheimerâ€™s disease, cancer, psychosis, Parkinsonâ€™s disease, and other serious conditions.
CBD-Intel aims to provide coverage of the topic by drawing on a large team of legal and market analysts, reporters and editors, in different countries. â€śWith ECigIntelligence we have found that a rapidly-developing industry has an urgent need for authoritative, unbiased, in-depth coverage of markets and regulation,â€ť said managing director Tim Phillips.
â€śWe believe that the CBD industry across Europe and the world will benefit from exactly the same approach â€“ reporting and analysis that is intelligent, insightful and independent.â€ť